Endocrine Abstracts

M shows an antiproliferative effect. In vivo, M reduces TSH in type 2 diabetes mellitus (T2DM) and DTC aggressiveness in DTC with T2DM. The aim of the study was to evaluate in DTC diabetic (Gr1, n=30 under M 1500 mg/day) and non-diabetic without (Gr2, n=83) or under M (gr3, n=84; M 1000 mg/day) the adjuvant role of M. Clinical and laboratory examinations were performed up to 24 months. At baseline the DTC groups were similar for age, gender, tumor stage, disease duration, L-T4 dosage and % of subjects under statins. Only BMI was higher in Gr1 and Gr3 respect to the Gr2. The RAI therapy was carried out with lower percentage (P=0.03) in the Gr1 than in the other groups. The patients did not have changes in oncological disease, BMI and L-T4 dosage. In DTC patients without T2DM compliance and tolerability towards M fairly. The most frequent adverse events were gastrointestinal. Several Gr3 patients showed weight loss. M adjuvant therapy resulted in a decrease of TSH levels in Gr3, initially higher (P<0.0001) compared to the Gr2, with overlapping values assessment at 12–24 months. After the beginning of M the in Gr3, insulin levels were significant (P=0.05) lower in Gr3 then in Gr2. In only Gr3 an improvement of the lipid profile was noted. Our data confirm the favorable evolution of the DTC and the high number of DTC with obesity and metabolic disorders. In our T2DM with DTC we have conflicting data (reduction in the use of RAI therapy vs higher number of subjects with detectable thyroglobulin). Difficult is the start of M in DTC patients, but its effects seem to favorable on TSH levels and lipidic status. Our data seem to indicate that in vivo M has a partial adjuvant action. More observation time and a wider coverage are needed.